Tag - ADVM

Developments

Adverum randomizes first patient in Phase 2 diabetic macular edema study

Adverum Biotechnologies (NASDAQ:ADVM) randomized the first patient in its INFINITY clinical trial evaluating ADVM-022 for the treatment of diabetic macular edema (DME). ADVM-022 is a one-time intravitreal gene therapy...

July 13, 2020

Markets

SVB Leerink starts Adverum Biotechnologies at OP; PT $17

SVB Leerink launched coverage of Adverum Biotechnologies (NASDAQ:ADVM) with an “outperform” rating and $17 price target. The stock closed at $10.33 on March 13. Adverum’s lead asset, ADVM-022, is in a Phase 1 trial as a...

March 16, 2020

Tag - ADVM

Adverum randomizes first patient in Phase 2 diabetic macular edema study

SVB Leerink starts Adverum Biotechnologies at OP; PT $17

General

More